Functional Significance of TDP-43 Mutations in Disease

Advances in Genetics

Volumn 91, Issue , 2015, Pages 1-53

  Buratti, Emanuele ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Aggregation; ALS; FTLD; Missense mutations; Neurodegeneration; RNA binding proteins; TDP 43

Indexed keywords

DNA BINDING PROTEIN; TDP-43 PROTEIN, HUMAN;

ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; GENETICS; HUMAN; METABOLISM; MUTATION;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES;

EID: 84945444891     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.adgen.2015.07.001     Document Type: Article

References (196)

1. Aggad D., Veriepe J., Tauffenberger A., Parker J.A. TDP-43 toxicity proceeds via calcium dysregulation and necrosis in aging Caenorhabditis elegans motor neurons. The Journal of Neuroscience 2014, 34(36):12093-12103. 10.1523/JNEUROSCI.2495-13.2014.
2. Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications 2006, 351(3):602-611.
3. Armstrong G.A., Drapeau P. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. The Journal of Neuroscience 2013, 33(4):1741-1752. 10.1523/JNEUROSCI.4003-12.2013.
4. Arnold E.S., Ling S.C., Huelga S.C., Lagier-Tourenne C., Polymenidou M., Ditsworth D., et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(8):E736-E745. 10.1073/pnas.1222809110.
5. Ash P.E., Zhang Y.J., Roberts C.M., Saldi T., Hutter H., Buratti E., et al. Neurotoxic effects of TDP-43 overexpression in C. elegans. Human Molecular Genetics 2010, 19(16):3206-3218. 10.1093/hmg/ddq230.
6. Audet J.N., Soucy G., Julien J.P. Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. Neuroscience 2012, pii:S0306-4522(11)01444-8. 10.1016/j.neuroscience.2011.12.047.
7. Austin J.A., Wright G.S., Watanabe S., Grossmann J.G., Antonyuk S.V., Yamanaka K., et al. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proceedings of the National Academy of Sciences of the United States of America 2014, 10.1073/pnas.1317317111.
8. Ayala Y.M., De Conti L., Avendano-Vazquez S.E., Dhir A., Romano M., D'Ambrogio A., et al. TDP-43 regulates its mRNA levels through a negative feedback loop. The EMBO Journal 2011, 30(2):277-288. 10.1038/emboj.2010.310.
9. Ayala Y.M., Pantano S., D'Ambrogio A., Buratti E., Brindisi A., Marchetti C., et al. Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. Journal of Molecular Biology 2005, 348(3):575-588.
10. Ayala Y.M., Zago P., D'Ambrogio A., Xu Y.F., Petrucelli L., Buratti E., et al. Structural determinants of the cellular localization and shuttling of TDP-43. Journal of Cell Science 2008, 121(Pt 22):3778-3785.
11. Banks G.T., Kuta A., Isaacs A.M., Fisher E.M. TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. Mammalian Genome 2008, 19(5):299-305.
12. Barmada S.J., Finkbeiner S. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Reviews in the Neurosciences 2010, 21(4):251-272.
13. Barmada S.J., Serio A., Arjun A., Bilican B., Daub A., Ando D.M., et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nature Chemical Biology 2014, 10.1038/nchembio.1563.
14. Barmada S.J., Skibinski G., Korb E., Rao E.J., Wu J.Y., Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. The Journal of Neuroscience 2010, 30(2):639-649.
15. Baumer D., Parkinson N., Talbot K. TARDBP in amyotrophic lateral sclerosis: identification of a novel variant but absence of copy number variation. Journal of Neurology, Neurosurgery, and Psychiatry 2009, 80(11):1283-1285.
16. Benajiba L., Le Ber I., Camuzat A., Lacoste M., Thomas-Anterion C., Couratier P., et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology 2009, 65(4):470-473.
17. Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(15):5803-5808. 10.1073/pnas.1202922109.
18. van Blitterswijk M., van Es M.A., Hennekam E.A., Dooijes D., van Rheenen W., Medic J., et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Human Molecular Genetics 2012, 21(17):3776-3784. 10.1093/hmg/dds199.
19. van Blitterswijk M., van Es M.A., Verbaan D., van Hilten J.J., Scheffer H., van de Warrenburg B.P., et al. Mutational analysis of TARDBP in Parkinson's disease. Neurobiology of Aging 2013, 34(5):1517 e1511-1513. 10.1016/j.neurobiolaging.2012.09.013.
20. van Blitterswijk M., Rademakers R., van den Berg L.H. Clinical variability and additional mutations in amyotrophic lateral sclerosis patients with p.N352S mutations in TARDBP. Neuropathology and Applied Neurobiology 2014, 40(3):356-358. 10.1111/nan.12099.
21. van Blitterswijk M., Vlam L., van Es M.A., van der Pol W.L., Hennekam E.A., Dooijes D., et al. Genetic overlap between apparently sporadic motor neuron diseases. PLoS One 2012, 7(11):e48983. 10.1371/journal.pone.0048983.
22. Borghero G., Floris G., Cannas A., Marrosu M.G., Murru M.R., Costantino E., et al. A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiology of Aging 2011, pii:S0197-4580(11)00225-9. 10.1016/j.neurobiolaging.2011.06.009.
23. Borghero G., Pugliatti M., Marrosu F., Marrosu M.G., Murru M.R., Floris G., et al. Genetic architecture of ALS in Sardinia. Neurobiology of Aging 2014, 35(12). 2882 e2887-2882 e2812. 10.1016/j.neurobiolaging.2014.07.012.
24. Borroni B., Archetti S., Del Bo R., Papetti A., Buratti E., Bonvicini C., et al. TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Research 2010, 13(5):509-517. 10.1089/rej.2010.1017.
25. Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S., et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Human Mutation 2009, 30(11):E974-E983.
26. Braun R.J., Sommer C., Carmona-Gutierrez D., Khoury C.M., Ring J., Buettner S., et al. Neurotoxic TDP-43 triggers mitochondrion-dependent programmed cell death in yeast. The Journal of Biological Chemistry 2011, 10.1074/jbc.M110.194852.
27. Brouwers N., Bettens K., Gijselinck I., Engelborghs S., Pickut B.A., Van Miegroet H., et al. Contribution of TARDBP to Alzheimer's disease genetic etiology. Journal of Alzheimer's Disease 2010, 21(2):423-430. 10.3233/JAD-2010-100198.
28. Budini M., Baralle F.E., Buratti E. Targeting TDP-43 in neurodegenerative diseases. Expert Opinion on Therapeutic Targets 2014, 18(6):617-632. 10.1517/14728222.2014.896905.
29. Budini M., Romano V., Avendano-Vazquez S.E., Bembich S., Buratti E., Baralle F.E. Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. Brain Research 2012, 1462:139-150. pii:S0006-8993(12)00308-3. 10.1016/j.brainres.2012.02.031.
30. Buratti E., Baralle F.E. The molecular links between TDP-43 dysfunction and neurodegeneration. Advances in Genetics 2009, 66:1-34.
31. Buratti E., Baralle F.E. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends in Biochemical Sciences 2012, 37(6):237-247. pii:S0968-0004(12)00046-1. 10.1016/j.tibs.2012.03.003.
32. Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., Mason M., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Molecular and Cellular Neuroscience 2013, 56C:355-364. 10.1016/j.mcn.2013.07.007.
33. Camdessanche J.P., Belzil V.V., Jousserand G., Rouleau G.A., Creac'h C., Convers P., et al. Sensory and motor neuronopathy in a patient with the A382P TDP-43 mutation. Orphanet Journal of Rare Diseases 2011, 6:4. 10.1186/1750-1172-6-4.
34. Cannas A., Borghero G., Floris G.L., Solla P., Chio A., Traynor B.J., et al. The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. Neurogenetics 2013, 10.1007/s10048-013-0360-2.
35. Chen A.K., Lin R.Y., Hsieh E.Z., Tu P.H., Chen R.P., Liao T.Y., et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. Journal of the American Chemical Society 2010, 132(4):1186-1187.
36. Chiang H.H., Andersen P.M., Tysnes O.B., Gredal O., Christensen P.B., Graff C. Novel TARDBP mutations in Nordic ALS patients. Journal of Human Genetics 2012, 10.1038/jhg.2012.24.
37. Chio A., Borghero G., Pugliatti M., Ticca A., Calvo A., Moglia C., et al. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Archives of Neurology 2011, 68(5):594-598. 10.1001/archneurol.2010.352.
38. Chio A., Calvo A., Mazzini L., Cantello R., Mora G., Moglia C. Extensive genetics of ALS: a population-based study in Italy. Neurology 2012, 79(19):1983-1989. PARALS. 10.1212/WNL.0b013e3182735d36.
39. Chio A., Calvo A., Moglia C., Restagno G., Ossola I., Brunetti M., et al. Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. Archives of Neurology 2010, 67(8):1002-1009.
40. Chio A., Restagno G., Brunetti M., Ossola I., Calvo A., Canosa A., et al. ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. Journal of Neurology, Neurosurgery, and Psychiatry 2012, 10.1136/jnnp-2012-302219.
41. Choksi D.K., Roy B., Chatterjee S., Yusuff T., Bakhoum M.F., Sengupta U., et al. TDP-43 Phosphorylation by casein kinase Iepsilon promotes oligomerization and enhances toxicity in vivo. Human Molecular Genetics 2014, 23(4):1025-1035. 10.1093/hmg/ddt498.
42. Cohen T.J., Hwang A.W., Unger T., Trojanowski J.Q., Lee V.M. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. The EMBO Journal 2011, 10.1038/emboj.2011.471.
43. Conforti F.L., Sproviero W., Simone I.L., Mazzei R., Valentino P., Ungaro C., et al. TARDBP gene mutations in south Italian patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 2011, 82(5):587-588. 10.1136/jnnp.2009.198309.
44. Corrado L., Ratti A., Gellera C., Buratti E., Castellotti B., Carlomagno Y., et al. High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Human Mutation 2009, 30(4):688-694.
45. Czell D., Andersen P.M., Morita M., Neuwirth C., Perren F., Weber M. Phenotypes in Swiss patients with familial ALS carrying TARDBP mutations. Neurodegenerative Diseases 2013, 10.1159/000345835.
46. D'Alton S., Altshuler M., Cannon A., Dickson D.W., Petrucelli L., Lewis J. Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling. PLoS One 2014, 9(1):e86513. 10.1371/journal.pone.0086513.
47. Dang T.N., Lim N.K., Grubman A., Li Q.X., Volitakis I., White A.R., et al. Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Frontiers in Aging Neuroscience 2014, 6:15. 10.3389/fnagi.2014.00015.
48. Daoud H., Valdmanis P.N., Kabashi E., Dion P., Dupre N., Camu W., et al. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics 2009, 46(2):112-114.
49. De Marco G., Lupino E., Calvo A., Moglia C., Buccinna B., Grifoni S., et al. Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathologica 2011, 121(5):611-622. 10.1007/s00401-010-0786-7.
50. Del Bo R., Ghezzi S., Corti S., Pandolfo M., Ranieri M., Santoro D., et al. TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. European Journal of Neurology 2009, 16(6):727-732.
51. Devlin A.C., Burr K., Borooah S., Foster J.D., Cleary E.M., Geti I., et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nature Communications 2015, 6:5999. 10.1038/ncomms6999.
52. Dewey C.M., Cenik B., Sephton C.F., Dries D.R., Mayer P., Good S.K., et al. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Molecular and Cellular Biology 2011, 31(5):1098-1108. 10.1128/MCB.01279-10.
53. Dong H., Xu L., Wu L., Wang X., Duan W., Li H., et al. Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS. Neuroscience 2014, 272:141-153. 10.1016/j.neuroscience.2014.04.032.
54. Duan W., Guo Y., Jiang H., Yu X., Li C. MG132 enhances neurite outgrowth in neurons overexpressing mutant TAR DNA-binding protein-43 via increase of HO-1. Brain Research 2011, pii:S0006-8993(11)00865-1. 10.1016/j.brainres.2011.05.006.
55. Duan W., Li X., Shi J., Guo Y., Li Z., Li C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience 2010, 169(4):1621-1629.
56. Espejo-Porras F., Piscitelli F., Verde R., Ramos J.A., Di Marzo V., de Lago E., et al. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of Neuroimmune Pharmacology 2015, 10.1007/s11481-015-9602-4.
57. Estes P.S., Boehringer A., Zwick R., Tang J.E., Grigsby B., Zarnescu D.C. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Human Molecular Genetics 2011, 20(12):2308-2321. 10.1093/hmg/ddr124.
58. Estes P.S., Daniel S.G., McCallum A.P., Boehringer A.V., Sukhina A.S., Zwick R.A., et al. Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a Drosophila model of amyotrophic lateral sclerosis. Disease Models and Mechanisms 2013, 10.1242/dmm.010710.
59. Evers M.M., Toonen L.J., van Roon-Mom W.M. Antisense oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug Delivery Reviews 2015, 10.1016/j.addr.2015.03.008.
60. Feiguin F., Godena V.K., Romano G., D'Ambrogio A., Klima R., Baralle F.E. Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Letters 2009, 583(10):1586-1592.
61. Finelli M.J., Liu K.X., Wu Y., Oliver P.L., Davies K.E. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations. Human Molecular Genetics 2015, 10.1093/hmg/ddv104.
62. Freibaum B.D., Chitta R.K., High A.A., Taylor J.P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. Journal of Proteome Research 2010, 9(2):1104-1120.
63. Fujita Y., Ikeda M., Yanagisawa T., Senoo Y., Okamoto K. Different clinical and neuropathologic phenotypes of familial ALS with A315E TARDBP mutation. Neurology 2011, 77(15):1427-1431. 10.1212/WNL.0b013e318232ab87.
64. Gelpi E., van der Zee J., Estrada A.T., van Broeckhoven C., Sanchez-Valle R. TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy. Neuropathology and Applied Neurobiology 2013, 10.1111/nan.12063.
65. Gendron T.F., Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. Journal of Molecular Neuroscience 2011, 45(3):486-499. 10.1007/s12031-011-9610-7.
66. Gendron T.F., Rademakers R., Petrucelli L. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. Journal of Alzheimer's Disease 2013, 33(Suppl. 1):S35-S45. 10.3233/JAD-2012-129036.
67. Gitcho M.A., Baloh R.H., Chakraverty S., Mayo K., Norton J.B., Levitch D., et al. TDP-43 A315T mutation in familial motor neuron disease. Annals of Neurology 2008, 63(4):535-538.
68. Guerreiro R.J., Schymick J.C., Crews C., Singleton A., Hardy J., Traynor B.J. TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis. PLoS One 2008, 3(6):e2450.
69. Guo W., Chen Y., Zhou X., Kar A., Ray P., Chen X., et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nature Structural and Molecular Biology 2011, 10.1038/nsmb.2053.
70. Guo Y., Wang Q., Zhang K., An T., Shi P., Li Z., et al. HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Research 2012, pii:S0006-8993(12)00650-6. 10.1016/j.brainres.2012.04.003.
71. Haidet-Phillips A.M., Gross S.K., Williams T., Tuteja A., Sherman A., Ko M., et al. Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Experimental Neurology 2013, 250:250-259. 10.1016/j.expneurol.2013.10.004.
72. Han J.H., Yu T.H., Ryu H.H., Jun M.H., Ban B.K., Jang D.J., et al. ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. Experimental Cell Research 2013, 319(13):1998-2005. 10.1016/j.yexcr.2013.05.025.
73. Hans F., Fiesel F.C., Strong J.C., Jackel S., Rasse T.M., Geisler S., et al. UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. The Journal of Biological Chemistry 2014, 289(27):19164-19179. 10.1074/jbc.M114.561704.
74. Herdewyn S., Cirillo C., Van Den Bosch L., Robberecht W., Vanden Berghe P., Van Damme P. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Molecular Neurodegeneration 2014, 9(1):24. 10.1186/1750-1326-9-24.
75. Homma T., Nagaoka U., Kawata A., Mochizuki Y., Kawakami H., Maruyama H., et al. Neuropathological features of Japanese familial amyotrophic lateral sclerosis with p.N352S mutation in TARDBP. Neuropathology and Applied Neurobiology 2014, 40(2):231-236. 10.1111/nan.12090.
76. Huang C., Huang B., Bi F., Yan L.H., Tong J., Huang J., et al. Profiling the genes affected by pathogenic TDP-43 in astrocytes. Journal of Neurochemistry 2014, 10.1111/jnc.12660.
77. Huang C., Tong J., Bi F., Zhou H., Xia X.G. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. Journal of Clinical Investigation 2012, 122(1):107-118. 10.1172/JCI59130.
78. Huang R., Fang D.F., Ma M.Y., Guo X.Y., Zhao B., Zeng Y., et al. TARDBP gene mutations among Chinese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging 2010, 33(5). 1015.e1-6.
79. Huey E.D., Ferrari R., Moreno J.H., Jensen C., Morris C.M., Potocnik F., et al. FUS and TDP43 genetic variability in FTD and CBS. Neurobiology of Aging 2011, pii:S0197-4580(11)00305-8. 10.1016/j.neurobiolaging.2011.08.004.
80. Igaz L.M., Kwong L.K., Chen-Plotkin A., Winton M.J., Unger T.L., Xu Y., et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. The Journal of Biological Chemistry 2009, 284(13):8516-8524.
81. Ihara R., Matsukawa K., Nagata Y., Kunugi H., Tsuji S., Chihara T., et al. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Human Molecular Genetics 2013, 22(22):4474-4484. 10.1093/hmg/ddt296.
82. Iida A., Kamei T., Sano M., Oshima S., Tokuda T., Nakamura Y., et al. Large-scale screening of TARDBP mutation in amyotrophic lateral sclerosis in Japanese. Neurobiology of Aging 2010, 33(4):786-790.
83. Jackrel M.E., Shorter J. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Disease Models and Mechanisms 2014, 10.1242/dmm.016113.
84. Janssens J., Wils H., Kleinberger G., Joris G., Cuijt I., Ceuterick-de Groote C., et al. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Molecular Neurobiology 2013, 10.1007/s12035-013-8427-5.
85. Jawaid A., Gapp K., Schulz P.E. Mitochondrial dysfunction and decrease in body weight of transgenic knock-in mouse model for TDP-43: the question of glucose?. The Journal of Biological Chemistry 2014, 289(26):18593. 10.1074/jbc.L114.572651.
86. Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. The Journal of Biological Chemistry 2009, 284(30):20329-20339.
87. Kabashi E., Lin L., Tradewell M.L., Dion P.A., Bercier V., Bourgouin P., et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Human Molecular Genetics 2010, 19(4):671-683.
88. Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics 2008, 40(5):572-574.
89. Kamada M., Maruyama H., Tanaka E., Morino H., Wate R., Ito H., et al. Screening for TARDBP mutations in Japanese familial amyotrophic lateral sclerosis. Journal of the Neurological Sciences 2009, 284(1-2):69-71.
90. Kenna K.P., McLaughlin R.L., Byrne S., Elamin M., Heverin M., Kenny E.M., et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. Journal of Medical Genetics 2013, 10.1136/jmedgenet-2013-101795.
91. Kim S.H., Shanware N.P., Bowler M.J., Tibbetts R.S. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. The Journal of Biological Chemistry 2010, 285(44):34097-34105.
92. Kim S.H., Shi Y., Hanson K.A., Williams L.M., Sakasai R., Bowler M.J., et al. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. The Journal of Biological Chemistry 2009, 284(12):8083-8092.
93. Kirby J., Goodall E.F., Smith W., Highley J.R., Masanzu R., Hartley J.A., et al. Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis. Neurogenetics 2010, 11(2):217-225.
94. Kovacs G.G., Murrell J.R., Horvath S., Haraszti L., Majtenyi K., Molnar M.J., et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Movement Disorders 2009, 24(12):1843-1847.
95. Kuhnlein P., Sperfeld A.D., Vanmassenhove B., Van Deerlin V., Lee V.M., Trojanowski J.Q., et al. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Archives of Neurology 2008, 65(9):1185-1189.
96. Laird A.S., Van Hoecke A., De Muynck L., Timmers M., Van den Bosch L., Van Damme P., et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS One 2010, 5(10):e13368. 10.1371/journal.pone.0013368.
97. Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Human Mutation 2013, 34(6):812-826. 10.1002/humu.22319.
98. Lauranzano E., Pozzi S., Pasetto L., Stucchi R., Massignan T., Paolella K., et al. Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain 2015, 138(Pt 4):974-991. 10.1093/brain/awv005.
99. Lemmens R., Race V., Hersmus N., Matthijs G., Van Den Bosch L., Van Damme P., et al. TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 2009, 80(3):354-355.
100. Li Z., Lu Y., Xu X.L., Gao F.B. The FTD/ALS-associated RNA-binding protein TDP-43 regulates the robustness of neuronal specification through microRNA-9a in Drosophila. Human Molecular Genetics 2013, 22(2):218-225. 10.1093/hmg/dds420.
101. Liachko N.F., Guthrie C.R., Kraemer B.C. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. The Journal of Neuroscience 2010, 30(48):16208-16219. 10.1523/JNEUROSCI.2911-10.2010.
102. Ling S.C., Albuquerque C.P., Han J.S., Lagier-Tourenne C., Tokunaga S., Zhou H., et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(30):13318-13323.
103. Liu-Yesucevitz L., Bilgutay A., Zhang Y.J., Vanderwyde T., Citro A., Mehta T., et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 2010, 5(10):e13250.
104. Liu-Yesucevitz L., Lin A.Y., Ebata A., Boon J.Y., Reid W., Xu Y.F., et al. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. The Journal of Neuroscience 2014, 34(12):4167-4174. 10.1523/JNEUROSCI.2350-13.2014.
105. Lu Y., Ferris J., Gao F.B. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Molecular Brain 2009, 2(1):30.
106. Lukavsky P.J., Daujotyte D., Tollervey J.R., Ule J., Stuani C., Buratti E., et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nature Structural and Molecular Biology 2013, 20(12):1443-1449. 10.1038/nsmb.2698.
107. Magrane J., Cortez C., Gan W.B., Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Human Molecular Genetics 2014, 23(6):1413-1424. 10.1093/hmg/ddt528.
108. Mandich P., Mantero V., Verdiani S., Gotta F., Caponnetto C., Bellone E., et al. Complexities of genetic counseling for ALS: a case of two siblings with discordant genetic test results. Journal of Genetics Counseling 2015, 10.1007/s10897-015-9831-y.
109. McDonald K.K., Aulas A., Destroismaisons L., Pickles S., Beleac E., Camu W., et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Human Molecular Genetics 2011, 20(7):1400-1410. 10.1093/hmg/ddr021.
110. Medina D.X., Orr M.E., Oddo S. Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiology of Aging 2014, 35(1):79-87. 10.1016/j.neurobiolaging.2013.07.006.
111. Mentula H.K., Tuovinen L., Penttila S., Suominen T., Udd B., Palmio J. TARDBP mutations are not a frequent cause of ALS in Finnish patients. Acta Myologica 2012, 31(2):134-138.
112. Millecamps S., Salachas F., Cazeneuve C., Gordon P., Bricka B., Camuzat A., et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics 2010, 47(8):554-560.
113. Miskiewicz K., Jose L.E., Yeshaw W.M., Valadas J.S., Swerts J., Munck S., et al. HDAC6 is a bruchpilot deacetylase that facilitates neurotransmitter release. Cell Reports 2014, 8(1):94-102. 10.1016/j.celrep.2014.05.051.
114. Mitchell J.C., Constable R., So E., Vance C., Scotter E., Glover L., et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathologica Communications 2015, 3(1):36. 10.1186/s40478-015-0212-4.
115. Moreno F., Rabinovici G.D., Karydas A., Miller Z., Hsu S.C., Legati A., et al. A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. Acta Neuropathologica Communications 2015, 3(1):19. 10.1186/s40478-015-0190-6.
116. Mosca L., Lunetta C., Tarlarini C., Avemaria F., Maestri E., Melazzini M., et al. Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiology of Aging 2012, pii:S0197-4580(12)00129-7. 10.1016/j.neurobiolaging.2012.01.108.
117. Mutihac R., Alegre-Abarrategui J., Gordon D., Farrimond L., Yamasaki-Mann M., Talbot K., et al. TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca(2)(+) signaling in motor neurons. Neurobiology of Disease 2015, 75:64-77. 10.1016/j.nbd.2014.12.010.
118. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314(5796):130-133.
119. Nishimura A.L., Shum C., Scotter E.L., Abdelgany A., Sardone V., Wright J., et al. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS One 2014, 9(3):e91269. 10.1371/journal.pone.0091269.
120. Nonaka T., Kametani F., Arai T., Akiyama H., Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Human Molecular Genetics 2009, 18(18):3353-3364.
121. Nozaki I., Arai M., Takahashi K., Hamaguchi T., Yoshikawa H., Muroishi T., et al. Familial ALS with G298S mutation in TARDBP: a comparison of CSF tau protein levels with those in sporadic ALS. Internal Medicine 2010, 49(12):1209-1212.
122. Okamoto K., Fujita Y., Hoshino E., Tamura Y., Fukuda T., Hasegawa M., et al. An autopsy case of familial amyotrophic lateral sclerosis with a TARDBP Q343R mutation. Neuropathology 2015, 10.1111/neup.12209.
123. Origone P., Accardo J., Verdiani S., Lamp M., Arnaldi D., Bellone E., et al. Neuroimaging features in C9orf72 and TARDBP double mutation with FTD phenotype. Neurocase 2014, 1-6. 10.1080/13554794.2014.951057.
124. Origone P., Caponnetto C., Bandettini Di Poggio M., Ghiglione E., Bellone E., Ferrandes G., et al. Enlarging clinical spectrum of FALS with TARDBP gene mutations: S393L variant in an Italian family showing phenotypic variability and relevance for genetic counselling. Amyotrophic Lateral Sclerosis 2010, 11(1-2):223-227.
125. Orru S., Manolakos E., Orru N., Kokotas H., Mascia V., Carcassi C., et al. High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients with amyotrophic lateral sclerosis. Clinical Genetics 2011, 10.1111/j.1399-0004.2011.01668.x.
126. Ozoguz A., Uyan O., Birdal G., Iskender C., Kartal E., Lahut S., et al. The distinct genetic pattern of ALS in Turkey and novel mutations. Neurobiology of Aging 2015, 36(4). 1764 e1769-1764 e1718. 10.1016/j.neurobiolaging.2014.12.032.
127. Pamphlett R., Luquin N., McLean C., Jew S.K., Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations. Neuropathology and Applied Neurobiology 2009, 35(2):222-225.
128. Perera N.D., Sheean R.K., Scott J.W., Kemp B.E., Horne M.K., Turner B.J. Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS One 2014, 9(3):e90449. 10.1371/journal.pone.0090449.
129. Pesiridis G.S., Lee V.M., Trojanowski J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Human Molecular Genetics 2009, 18(R2):R156-R162.
130. Pesiridis G.S., Tripathy K., Tanik S., Trojanowski J.Q., Lee V.M. A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. The Journal of Biological Chemistry 2011, 286(21):18845-18855. 10.1074/jbc.M111.231118.
131. Praline J., Vourc'h P., Guennoc A.M., Veyrat-Durebex C., Corcia P. Co-occurrence of progressive anarthria with an S393L TARDBP mutation and ALS within a family. Amyotrophic Lateral Sclerosis 2011, 10.3109/17482968.2011.598168.
132. Qin H., Lim L.Z., Wei Y., Song J. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(52):18619-18624. 10.1073/pnas.1413994112.
133. Quadri M., Cossu G., Saddi V., Simons E.J., Murgia D., Melis M., et al. Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics 2011, 10.1007/s10048-011-0288-3.
134. Rayaprolu S., Fujioka S., Traynor S., Soto-Ortolaza A.I., Petrucelli L., Dickson D.W., et al. TARDBP mutations in Parkinson's disease. Parkinsonism and Related Disorders 2013, 19(3):312-315. 10.1016/j.parkreldis.2012.11.003.
135. Ritson G.P., Custer S.K., Freibaum B.D., Guinto J.B., Geffel D., Moore J., et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. The Journal of Neuroscience 2010, 30(22):7729-7739. 10.1523/JNEUROSCI.5894-09.2010.
136. Rojas F., Cortes N., Abarzua S., Dyrda A., van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Frontiers in Cellular Neuroscience 2014, 8:24. 10.3389/fncel.2014.00024.
137. Rojas F., Gonzalez D., Cortes N., Ampuero E., Hernandez D.E., Fritz E., et al. Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling. Frontiers in Cellular Neuroscience 2015, 9:203. 10.3389/fncel.2015.00203.
138. Rollinson S., Snowden J.S., Neary D., Morrison K.E., Mann D.M., Pickering-Brown S.M. TDP-43 gene analysis in frontotemporal lobar degeneration. Neuroscience Letters 2007, 419(1):1-4.
139. Romano M., Buratti E., Romano G., Klima R., Del Bel Belluz L., Stuani C., et al. Evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with human and Drosophila TAR DNA-binding protein 43 (TDP-43). The Journal of Biological Chemistry 2014, 289(10):7121-7130. 10.1074/jbc.M114.548859.
140. Romano M., Feiguin F., Buratti E. Drosophila answers to TDP-43 proteinopathies. Journal of Amino Acids 2012, 2012:356081. 10.1155/2012/356081.
141. Romano V., Quadri Z., Baralle F.E., Buratti E. The structural integrity of TDP-43 N-terminus is required for efficient aggregate entrapment and consequent loss of protein function. Prion 2015, 9(1):1-9. 10.1080/19336896.2015.1011885.
142. Rothstein J.D. TDP-43 in amyotrophic lateral sclerosis: pathophysiology or patho-babel?. Annals of Neurology 2007, 61(5):382-384.
143. Rutherford N.J., Zhang Y.J., Baker M., Gass J.M., Finch N.A., Xu Y.F., et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genetics 2008, 4(9):e1000193.
144. Sabatelli M., Zollino M., Conte A., Del Grande A., Marangi G., Lucchini M., et al. Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. Neurobiology of Aging 2015, 36(5). 2005 e2005-2005 e2013. 10.1016/j.neurobiolaging.2015.02.009.
145. Schmid B., Hruscha A., Hogl S., Banzhaf-Strathmann J., Strecker K., van der Zee J., et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(13):4986-4991. 10.1073/pnas.1218311110.
146. Scotter E.L., Chen H.J., Shaw C.E. TDP-43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets. Neurotherapeutics 2015, 12(2):352-363. 10.1007/s13311-015-0338-x.
147. Serio A., Bilican B., Barmada S.J., Ando D.M., Zhao C., Siller R., et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(12):4697-4702. 10.1073/pnas.1300398110.
148. Solski J.A., Yang S., Nicholson G.A., Luquin N., Williams K.L., Fernando R., et al. A novel TARDBP insertion/deletion mutation in the flail arm variant of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2012, 10.3109/17482968.2012.662690.
149. Soong B.W., Lin K.P., Guo Y.C., Lin C.C., Tsai P.C., Liao Y.C., et al. Extensive molecular genetic survey of Taiwanese patients with amyotrophic lateral sclerosis. Neurobiology of Aging 2014, 10.1016/j.neurobiolaging.2014.05.008.
150. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319(5870):1668-1672.
151. Stallings N.R., Puttaparthi K., Dowling K.J., Luther C.M., Burns D.K., Davis K., et al. TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS One 2013, 8(8):e71793. 10.1371/journal.pone.0071793.
152. Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiology of Disease 2010, 40(2):404-414.
153. Stribl C., Samara A., Trumbach D., Peis R., Neumann M., Fuchs H., et al. Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. The Journal of Biological Chemistry 2014, 289(15):10769-10784. 10.1074/jbc.M113.515940.
154. Sun C.S., Wang C.Y., Chen B.P., He R.Y., Liu G.C., Wang C.H., et al. The influence of pathological mutations and proline substitutions in TDP-43 Glycine-rich peptides on its amyloid properties and cellular toxicity. PLoS One 2014, 9(8):e103644. 10.1371/journal.pone.0103644.
155. Suzuki H., Lee K., Matsuoka M. TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. The Journal of Biological Chemistry 2011, 286(15):13171-13183. 10.1074/jbc.M110.197483.
156. Swanson M.S. Rectifying RNA splicing errors in hereditary neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America 2015, 112(9):2637-2638. 10.1073/pnas.1500976112.
157. Swarup V., Audet J.N., Phaneuf D., Kriz J., Julien J.P. Abnormal regenerative responses and impaired axonal outgrowth after nerve crush in TDP-43 transgenic mouse models of amyotrophic lateral sclerosis. The Journal of Neuroscience 2012, 32(50):18186-18195. 10.1523/JNEUROSCI.2267-12.2012.
158. Swarup V., Phaneuf D., Bareil C., Robertson J., Rouleau G.A., Kriz J., et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011, 10.1093/brain/awr159.
159. Swarup V., Phaneuf D., Dupre N., Petri S., Strong M., Kriz J., et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. The Journal of Experimental Medicine 2011, 208(12):2429-2447. 10.1084/jem.20111313.
160. Synofzik M., Born C., Rominger A., Lummel N., Schols L., Biskup S., et al. Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. Neurobiology of Aging 2014, 35(5):1212 e1211-1215. 10.1016/j.neurobiolaging.2013.10.092.
161. Tamaoka A., Arai M., Itokawa M., Arai T., Hasegawa M., Tsuchiya K., et al. TDP-43 M337V mutation in familial amyotrophic lateral sclerosis in Japan. Internal Medicine 2010, 49(4):331-334.
162. Tian T., Huang C., Tong J., Yang M., Zhou H., Xia X.G. TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. International Journal of Biological Sciences 2011, 7(2):234-243.
163. Ticozzi N., LeClerc A.L., van Blitterswijk M., Keagle P., McKenna-Yasek D.M., Sapp P.C., et al. Mutational analysis of TARDBP in neurodegenerative diseases. Neurobiology of Aging 2011, 32(11):2096-2099. pii:S0197-4580(09)00388-1. 10.1016/j.neurobiolaging.2009.11.018.
164. Ticozzi N., Vance C., Leclerc A.L., Keagle P., Glass J.D., McKenna-Yasek D., et al. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2011, 156B(3):285-290. 10.1002/ajmg.b.31158.
165. Tong J., Huang C., Bi F., Wu Q., Huang B., Liu X., et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. The EMBO Journal 2013, 32(13):1917-1926. 10.1038/emboj.2013.122.
166. Tong J., Huang C., Bi F., Wu Q., Huang B., Zhou H. XBP1 depletion precedes ubiquitin aggregation and golgi fragmentation in TDP-43 transgenic rats. Journal of Neurochemistry 2012, 123(3):406-416. 10.1111/jnc.12014.
167. Tran L.T., Gentil B.J., Sullivan K.E., Durham H.D. The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43. Journal of Neurochemistry 2014, 10.1111/jnc.12738.
168. Tripathi V.B., Baskaran P., Shaw C.E., Guthrie S. Tar DNA-binding protein-43 (TDP-43) regulates axon growth in vitro and in vivo. Neurobiology of Disease 2014, 65:25-34. 10.1016/j.nbd.2014.01.004.
169. Tripathi V., Guthrie S., Shaw C., Marinela V., Al-Chalabi A., Vance C., et al. POD09 using the chick embryo model system to study the neurotoxicity of TDP43. Journal of Neurology, Neurosurgery, and Psychiatry 2010, 81(11):e44.
170. Tsai C.P., Soong B.W., Lin K.P., Tu P.H., Lin J.L., Lee Y.C. FUS, TARDBP, and SOD1 mutations in a Taiwanese cohort with familial ALS. Neurobiology of Aging 2011, 32(3):553 e513-521. pii:S0197-4580(10)00172-7. 10.1016/j.neurobiolaging.2010.04.009.
171. Vaccaro A., Patten S.A., Aggad D., Julien C., Maios C., Kabashi E., et al. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiology of Disease 2013, 55:64-75. 10.1016/j.nbd.2013.03.015.
172. Vaccaro A., Tauffenberger A., Aggad D., Rouleau G., Drapeau P., Parker J.A. Mutant TDP-43 and FUS cause age-dependent paralysis and neurodegeneration in C. elegans. PLoS One 2012, 7(2):e31321. pii:PONE-D-11-19868. 10.1371/journal.pone.0031321.
173. Van Deerlin V.M., Leverenz J.B., Bekris L.M., Bird T.D., Yuan W., Elman L.B., et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. The Lancet Neurology 2008, 7(5):409-416.
174. Vanden Broeck L., Kleinberger G., Chapuis J., Gistelinck M., Amouyel P., Van Broeckhoven C., et al. Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. Neurobiology of Aging 2015, 36(2):1121-1129. 10.1016/j.neurobiolaging.2014.09.001.
175. Voigt A., Herholz D., Fiesel F.C., Kaur K., Muller D., Karsten P., et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One 2010, 5(8):e12247. 10.1371/journal.pone.0012247.
176. Vrabec K., Koritnik B., Leonardis L., Dolenc-Groselj L., Zidar J., Smith B., et al. Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population. Neurobiology of Aging 2015, 36(3):1601 e1617-1620. 10.1016/j.neurobiolaging.2014.11.011.
177. Walker A.K., Soo K.Y., Sundaramoorthy V., Parakh S., Ma Y., Farg M.A., et al. ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS One 2013, 8(11):e81170. 10.1371/journal.pone.0081170.
178. Wang W., Li L., Lin W.L., Dickson D.W., Petrucelli L., Zhang T., et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Human Molecular Genetics 2013, 22(23):4706-4719. 10.1093/hmg/ddt319.
179. Watanabe S., Kaneko K., Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. The Journal of Biological Chemistry 2013, 288(5):3641-3654. 10.1074/jbc.M112.433615.
180. Wegorzewska I., Baloh R.H. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegenerative Diseases 2011, 8(4):262-274. 10.1159/000321547.
181. Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(44):18809-18814.
182. Williams K.L., Durnall J.C., Thoeng A.D., Warraich S.T., Nicholson G.A., Blair I.P. A novel TARDBP mutation in an Australian amyotrophic lateral sclerosis kindred. Journal of Neurology, Neurosurgery, and Psychiatry 2009, 80(11):1286-1288.
183. Winton M.J., Igaz L.M., Wong M.M., Kwong L.K., Trojanowski J.Q., Lee V.M. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. The Journal of Biological Chemistry 2008, 283(19):13302-13309.
184. Winton M.J., Van Deerlin V.M., Kwong L.K., Yuan W., Wood E.M., Yu C.E., et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Letters 2008, 582(15):2252-2256.
185. Wu L.S., Cheng W.C., Shen C.K. Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions. Journal of Biomedical Science 2013, 20:33. 10.1186/1423-0127-20-33.
186. Xiong H.L., Wang J.Y., Sun Y.M., Wu J.J., Chen Y., Qiao K., et al. Association between novel TARDBP mutations and Chinese patients with amyotrophic lateral sclerosis. BMC Medical Genetics 2010, 11:8.
187. Xu M., Zhu L., Liu J., Yang Y., Wu J.Y., Wang C. Characterization of beta-domains in C-terminal fragments of TDP-43 by scanning tunneling microscopy. Journal of Structural Biology 2013, 181(1):11-16. 10.1016/j.jsb.2012.10.011.
188. Xu Y.F., Zhang Y.J., Lin W.L., Cao X., Stetler C., Dickson D.W., et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Molecular Neurodegeneration 2011, 6:73. 10.1186/1750-1326-6-73.
189. Yamashita T., Hideyama T., Hachiga K., Teramoto S., Takano J., Iwata N., et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nature Communications 2012, 3:1307. 10.1038/ncomms2303.
190. Yan S., Wang C.E., Wei W., Gaertig M.A., Lai L., Li S., et al. TDP-43 causes differential pathology in neuronal versus glial cells in the mouse brain. Human Molecular Genetics 2014, 10.1093/hmg/ddt662.
191. Ye C.H., Lu X.L., Zheng M.Y., Zhen J., Li Z.P., Shi L., et al. Absence of mutations in exon 6 of the TARDBP gene in 207 Chinese patients with sporadic amyotrophic lateral sclerosis. PLoS One 2013, 8(7):e68106. 10.1371/journal.pone.0068106.
192. Yokoseki A., Shiga A., Tan C.F., Tagawa A., Kaneko H., Koyama A., et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Annals of Neurology 2008, 63(4):538-542.
193. Zhang Y.J., Caulfield T., Xu Y.F., Gendron T.F., Hubbard J., Stetler C., et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Human Molecular Genetics 2013, 22(15):3112-3122. 10.1093/hmg/ddt166.
194. Zhou H., Huang C., Chen H., Wang D., Landel C.P., Xia P.Y., et al. transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genetics 2010, 6(3):e1000887.
195. Zhu L., Xu M., Yang M., Yang Y., Li Y., Deng J., et al. An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel beta-structure and induces TDP-43 redistribution. Human Molecular Genetics 2014, 10.1093/hmg/ddu409.
196. Zou Z.Y., Peng Y., Wang X.N., Liu M.S., Li X.G., Cui L.Y. Screening of the TARDBP gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. Neurobiology of Aging 2012, pii:S0197-4580(12)00227-8. 10.1016/j.neurobiolaging.2012.03.014.